Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRD004
MIFTS: 49

Prediabetes Syndrome

Categories: Blood diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prediabetes Syndrome

About this section

MalaCards integrated aliases for Prediabetes Syndrome:

Name: Prediabetes Syndrome 12 15 17 72
Prediabetic State 12 55 44
Prediabetes 12 43 15

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11716
MeSH 44 D011236
NCIt 50 C122685
SNOMED-CT 68 15777000 9414007
ICD10 33 R73.03
UMLS 72 C0362046
Sources

Summaries for Prediabetes Syndrome

About this section
MedlinePlus : 43 Prediabetes means you have blood glucose, or blood sugar, levels that are higher than normal but not high enough to be called diabetes. Glucose comes from the foods you eat. Too much glucose in your blood can damage your body over time. If you have prediabetes, you are more likely to develop type 2 diabetes, heart disease, and stroke. Most people with prediabetes don't have any symptoms. Your doctor can use an A1C test or another blood test to find out if your blood glucose levels are higher than normal. If you are 45 years old or older, your doctor may recommend that you be tested for prediabetes, especially if you are overweight. Losing weight - at least 5 to 10 percent of your starting weight - can prevent or delay diabetes or even reverse prediabetes. That's 10 to 20 pounds for someone who weighs 200 pounds. You can lose weight by cutting down on the amount of calories and fat you eat and being physically active at least 30 minutes a day. Being physically active makes your body's insulin work better. Your doctor may also prescribe medicine to help control the amount of glucose in your blood. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prediabetes Syndrome, also known as prediabetic state, is related to fatty liver disease and fatty liver disease, nonalcoholic 1. An important gene associated with Prediabetes Syndrome is INS (Insulin), and among its related pathways/superpathways are Glucose / Energy Metabolism and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Insulin glargine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 75 Prediabetes is the precursor stage before diabetes mellitus in which not all of the symptoms required to... more...

Sources

Related Diseases for Prediabetes Syndrome

About this section

Diseases related to Prediabetes Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 32.6 LEP INS IL6 ADIPOQ
2 fatty liver disease, nonalcoholic 1 31.1 LEP INS ADIPOQ
3 gestational diabetes 30.9 TCF7L2 LEP INS ADIPOQ
4 peripheral nervous system disease 30.8 INS IL6 ALB
5 lipid metabolism disorder 30.7 PPARG LEP INS CRP COG2 ADIPOQ
6 atherosclerosis susceptibility 30.7 PPARG INS IL6 CRP ADIPOQ
7 cerebrovascular disease 30.6 INS IL6 CRP ADIPOQ
8 peripheral vascular disease 30.5 IL6 CRP ALB
9 coronary heart disease 1 30.5 INS IL6 CRP COG2 ADIPOQ
10 acanthosis nigricans 30.5 PPARG LEP INS ADIPOQ
11 liver disease 30.3 LEP INS IL6 ALB ADIPOQ
12 anovulation 30.3 LEP INS CRP
13 sleep apnea 30.3 LEP INS IL6 CRP ADIPOQ
14 hypertension, essential 30.2 LEP INS ALB ADIPOQ
15 coronary stenosis 30.2 IL6 CRP ALB
16 uremia 30.1 LEP INS CRP ALB
17 kidney disease 30.1 INS IL6 CRP ALB ADIPOQ
18 sleep disorder 30.1 LEP INS IL6 CRP
19 acute insulin response 30.0 TCF7L2 INS GCG CRP
20 deficiency anemia 30.0 IL6 CRP ALB
21 acute cystitis 30.0 IL6 CRP ALB
22 end stage renal failure 30.0 LEP IL6 CRP ALB
23 vascular disease 30.0 PPARG INS IL6 CRP ALB ADIPOQ
24 endocarditis 29.9 IL6 CRP ALB
25 diabetes mellitus, insulin-dependent 29.8 INS IL6 GCG GAD1 ALB
26 arteriosclerosis 29.7 PPARG INS IL6 CRP COG2 ADIPOQ
27 maturity-onset diabetes of the young 29.6 INS GCG DPP4 CRP
28 myocardial infarction 29.5 INS IL6 CRP COG2 ALB ADIPOQ
29 prader-willi syndrome 29.4 LEP INS GCG ADIPOQ
30 hyperglycemia 29.4 PPARG LEP INS GIP GCG DPP4
31 proteasome-associated autoinflammatory syndrome 1 29.4 PPARG INS IL6 CRP ALB ADIPOQ
32 arteries, anomalies of 29.1 PPARG LEP INS IL6 CRP COG2
33 glucose intolerance 28.6 PPARG LEP INS GCG DPP4 CRP
34 diabetes mellitus 28.5 TCF7L2 PPARG LEP INS IL6 GIP
35 body mass index quantitative trait locus 11 27.8 PPARG LEP INS IL6 GIP GCG
36 glucose metabolism disease 26.5 TCF7L2 PPARG LEP INS IL6 GIP
37 maturity-onset diabetes of the young, type 1 26.0 TCF7L2 PPARG LEP INS IL6 GCG
38 diabetes mellitus, noninsulin-dependent 25.9 TCF7L2 PPARG LEP INS IL6 GIP
39 polycystic ovary syndrome 11.5
40 non-alcoholic steatohepatitis 11.5
41 malignant otitis externa 10.7 INS CRP
42 hyperinsulinism 10.6
43 autoimmune polyendocrine syndrome, type ii 10.6 INS GAD1
44 idiopathic recurrent pericarditis 10.6 LEP ADIPOQ
45 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.6 LEP INS
46 idiopathic edema 10.5 PPARG INS ADIPOQ
47 severe nonproliferative diabetic retinopathy 10.5 INS ALB
48 lipodystrophy, congenital generalized, type 1 10.5 LEP INS ADIPOQ
49 lipodystrophy, familial partial, type 1 10.5 PPARG LEP INS
50 body mass index quantitative trait locus 1 10.5

Graphical network of the top 20 diseases related to Prediabetes Syndrome:



Diseases related to Prediabetes Syndrome
Sources

Symptoms & Phenotypes for Prediabetes Syndrome

About this section

MGI Mouse Phenotypes related to Prediabetes Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 ADIPOQ ALB COG2 CRP DPP4 GAD1
2 growth/size/body region MP:0005378 10.14 ADIPOQ CNBP COG2 DPP4 GAD1 GIP
3 endocrine/exocrine gland MP:0005379 10.09 ADIPOQ ALB DPP4 GAD1 IL6 INS
4 digestive/alimentary MP:0005381 10 ALB GAD1 GIP IL6 INS LEP
5 adipose tissue MP:0005375 9.95 ADIPOQ IL6 INS LEP PPARG TCF7L2
6 liver/biliary system MP:0005370 9.87 ADIPOQ ALB IL6 INS LEP PPARG
7 muscle MP:0005369 9.8 ADIPOQ ALB IL6 INS LEP PPARG
8 neoplasm MP:0002006 9.63 ADIPOQ ALB IL6 LEP PPARG TCF7L2
9 renal/urinary system MP:0005367 9.5 ADIPOQ ALB IL6 INS LEP PPARG
10 skeleton MP:0005390 9.23 ADIPOQ CNBP GAD1 IL6 INS LEP
Sources

Drugs & Therapeutics for Prediabetes Syndrome

About this section

Drugs for Prediabetes Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
5
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
6
Saxagliptin Approved Phase 4 361442-04-8 11243969
7
Phylloquinone Approved, Investigational Phase 4 84-80-0
8
Bilberry Approved, Experimental Phase 4
9
Nitric Oxide Approved Phase 4 10102-43-9 145068
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Hydroxychloroquine Approved Phase 4 118-42-3 3652
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Atorvastatin Approved Phase 4 134523-00-5 60823
15
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
16
Liraglutide Approved Phase 4 204656-20-2 44147092
17
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
18
Pravastatin Approved Phase 4 81093-37-0 54687
19
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
20
Canagliflozin Approved Phase 4 842133-18-0
21
Ethanol Approved Phase 4 64-17-5 702
22
Zinc Approved, Investigational Phase 4 7440-66-6 32051
23
Amlodipine Approved Phase 4 88150-42-9 2162
24
Glucagon Approved Phase 4 16941-32-5
25
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
26
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
27
Sodium citrate Approved, Investigational Phase 4 68-04-2
28
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
29
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31 Menaquinone Investigational Phase 4 1182-68-9
32
Menatetrenone Investigational Phase 4 863-61-6 5282367
33
Voglibose Investigational Phase 4 83480-29-9 444020
34 Coagulants Phase 4
35 Antifibrinolytic Agents Phase 4
36 naphthoquinone Phase 4
37 Vitamin K Phase 4
38 Hemostatics Phase 4
39 Vitamin K 2 Phase 4
40 Vitamin MK 7 Phase 4
41 Anthocyanidin Phase 4
42 Black Currant Phase 4
43 Anti-Asthmatic Agents Phase 4
44 Endothelium-Dependent Relaxing Factors Phase 4
45 Bronchodilator Agents Phase 4
46 Alpha-lipoic Acid Phase 4
47 Thioctic Acid Phase 4
48 calcium channel blockers Phase 4
49 Biguanides Phase 4
50 Serotonin Receptor Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 718)
# Name Status NCT ID Phase Drugs
1 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
2 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
3 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
4 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
5 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
6 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
7 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
8 Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
9 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
10 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
11 Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes Completed NCT02754739 Phase 4 Pravastatin;Placebo (for Pravastatin)
12 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
13 Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
14 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Completed NCT02167620 Phase 4 Metformin;Placebo
15 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
16 Diet and Exercise in Type 2 Diabetes and Prediabetes Completed NCT00928005 Phase 4
17 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo
18 The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
19 MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease Completed NCT02226510 Phase 4 Metformin XL;Placebo
20 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
21 Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care Completed NCT01365013 Phase 4
22 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
23 Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study Completed NCT03474562 Phase 4 Duowell®;Monorova® + Amlopin®
24 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
25 The Effect of Vitamin K Supplementation on Glucose Metabolism Completed NCT00960973 Phase 4 Menatetrenone;Placebo
26 Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Effect of Vitamin D Supplementation on Fasting Glucose and IL-10 in Arab Women With Impaired Fasting Glucose. Completed NCT00877123 Phase 4 Oral vitamin D 100,000 IU;Placebo
27 Acute Impact of IM Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics Completed NCT01411930 Phase 4 Intramuscular olanzapine, aripiprazole;Intramuscular aripiprazole, olanzapine
28 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
29 The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion Completed NCT01056497 Phase 4 alpha lipoic acid
30 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
31 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
32 Effect of Saxagliptin (DPP-4 Inhibitor) on Endothelial Progenitor Cells (EPCs) as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients Completed NCT02024477 Phase 4 Saxagliptin;Placebo
33 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
34 A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
35 Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study Recruiting NCT02981121 Phase 4 Metformin
36 A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension Recruiting NCT03532620 Phase 4 Pitavastatin Calcium;Atorvastatin Calcium
37 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Recruiting NCT03917784 Phase 4 Curcumin;Starch
38 Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients Recruiting NCT03774108 Phase 4 Metformin Hydrochloride 850 MG
39 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Recruiting NCT02744976 Phase 4 Metformin
40 Improving Beta Cell Function in Mexican American Women With Prediabetes Recruiting NCT02488057 Phase 4 Liraglutide
41 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT) Recruiting NCT02915198 Phase 4 Metformin XR;Placebo
42 Cardiovascular Effects of GLP-1 Receptor Activation Recruiting NCT03101930 Phase 4 Liraglutide;Sitagliptin;Placebos;Exendin (9-39)
43 The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose Recruiting NCT01816997 Phase 4 Pravastatin;Rosuvastatin;Control
44 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
45 Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes Recruiting NCT02964585 Phase 4 Canagliflozin;Placebo
46 A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China. Active, not recruiting NCT03441750 Phase 4 metformin
47 Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment Active, not recruiting NCT03006471 Phase 4 Dapagliflozin;Placebo - Cap
48 Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes Active, not recruiting NCT03029390 Phase 4 Metformin
49 The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study Not yet recruiting NCT03938389 Phase 4 Sacubitril-Valsartan Tab 97-103 MG;Valsartan 160mg;Placebo Oral Tablet
50 MaasFlex: Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxidation, Glucose Metabolism and Muscle Mitochondrial Function in Individuals With Impaired Glucose Homeostasis Not yet recruiting NCT03721874 Phase 4 Dapagliflozin 10mg;Placebo matching to Dapagliflozin 10 mg

Search NIH Clinical Center for Prediabetes Syndrome

Cochrane evidence based reviews: prediabetic state

Sources

Genetic Tests for Prediabetes Syndrome

About this section
Sources

Anatomical Context for Prediabetes Syndrome

About this section

MalaCards organs/tissues related to Prediabetes Syndrome:

41
Testes, Heart, Endothelial, Kidney, Liver, Bone, Brain
Sources

Publications for Prediabetes Syndrome

About this section

Articles related to Prediabetes Syndrome:

(show top 50) (show all 358)
# Title Authors PMID Year
1
Vitamin D Supplementation and Prevention of Type 2 Diabetes. 17
31173679 2019
2
The effect of zinc supplementation in pre-diabetes: A protocol for systematic review and meta-analysis. 17
31277146 2019
3
Association of Sonographically Assessed Visceral and Subcutaneous Abdominal Fat with Insulin Resistance in Prediabetes. 17
31299843 2019
4
Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. 9 38
20425581 2010
5
Metabolic implications of dietary trans-fatty acids. 9 38
19584878 2009
6
Dietary fructose and the metabolic syndrome. 9 38
18301272 2008
7
Increasing the fat-to-carbohydrate ratio in a high-fat diet prevents the development of obesity but not a prediabetic state in rats. 9 38
17608620 2007
8
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. 9 38
17877545 2007
9
Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells. 9 38
17583797 2007
10
The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD. 9 38
16879779 2006
11
Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. 9 38
16673209 2006
12
Pathophysiology of prediabetes. 9 38
16570762 2005
13
Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. 9 38
16248830 2005
14
Insulin resistance and metformin in polycystic ovary syndrome. 9 38
15262344 2004
15
Hyperglycemia as a cardiovascular risk factor. 9 38
14678859 2003
16
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. 9 38
14517163 2003
17
[Diabetes mellitus and the cerebrovascular disease]. 9 38
15775195 2003
18
Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. 9 38
14511928 2003
19
Insulin resistance, inflammation, and the prediabetic state. 9 38
12957323 2003
20
Insulin resistance--the new goal! 9 38
12795774 2003
21
Stress induced disturbances of the HPA axis: a pathway to Type 2 diabetes? 9 38
12601304 2003
22
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. 9 38
12466345 2002
23
The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis. 9 38
11940051 2002
24
Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis. 9 38
10714759 2000
25
Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. 9 38
10704163 2000
26
Defective function of the proteasome in autoimmunity: involvement of impaired NF-kappaB activation. 9 38
11467344 2000
27
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus. 9 38
9628241 1998
28
Central role of the adipocyte in insulin resistance. 9 38
10212835 1998
29
Characterization of the prediabetic state. 9 38
9324118 1997
30
Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. 9 38
9049487 1997
31
Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. 9 38
8610702 1996
32
The insulin-dependent patient: perceptions and preferences. 9 38
7600752 1995
33
Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. 9 38
7900697 1995
34
Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? 9 38
7914964 1994
35
Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes. 9 38
7681983 1993
36
Clinical studies with CE-inhibitors in diabetes. 9 38
2202631 1990
37
An evaluation of the effects of general practitioner-supported patient noncommunicable diseases control model in Shanghai, China. 38
31364199 2019
38
Efficacy of lifestyle interventions in the reversion to normoglycemia in Korean prediabetics: One-year results from a randomised controlled trial. 38
30583933 2019
39
[Precise diagnosis of prediabetic state of autoimmune type 1 diabetes mellitus]. 38
31137121 2019
40
Tracking lipid profile and atherogenic indices in the prediabetics of Andaman Nicobar Islands: A retrospective hospital-based study. 38
31041260 2019
41
Early metabolic changes in the gut leads to higher expression of intestinal alpha glucosidase and thereby causes enhanced postprandial spikes. 38
30553872 2019
42
Treating prediabetes: why and how should we do it? 38
30371047 2019
43
Elevated free fatty acid level is associated with insulin-resistant state in nondiabetic Chinese people. 38
30705599 2019
44
Plasma levels of free fatty acids correlate with type 2 diabetes mellitus. 38
29943387 2018
45
Do Hospital Doctors Screen for Diabetes? 38
30296790 2018
46
Current and emerging pharmacotherapy for prediabetes: are we moving forward? 38
30198813 2018
47
Functional Effects of the Buckwheat Iminosugar d-Fagomine on Rats with Diet-Induced Prediabetes. 38
29979820 2018
48
Proteomics of the Rat Myocardium during Development of Type 2 Diabetes Mellitus Reveals Progressive Alterations in Major Metabolic Pathways. 38
29847139 2018
49
Influence of Health Behaviors and Occupational Stress on Prediabetic State among Male Office Workers. 38
29904033 2018
50
Fatty Acid-Stimulated Insulin Secretion vs. Lipotoxicity. 38
29921789 2018
Sources

Variations for Prediabetes Syndrome

About this section
Sources

Expression for Prediabetes Syndrome

About this section
Search GEO for disease gene expression data for Prediabetes Syndrome.
Sources

Pathways for Prediabetes Syndrome

About this section

Pathways related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Glucose / Energy Metabolism 4
12.26 PPARG INS GCG GAD1 ADIPOQ
2
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.17 PPARG LEP INS ADIPOQ
3
Selenium Micronutrient Network 1
Show member pathways
 12.07 INS IL6 CRP ALB
5
Peptide hormone metabolism 66
Show member pathways
 11.89 TCF7L2 LEP INS GIP GCG DPP4
6
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.79 INS IL6 ALB
7
Adipogenesis 1
11.78 PPARG LEP INS IL6 ADIPOQ
8
Differentiation of white and brown adipocyte 1
10.9 PPARG LEP ADIPOQ
9
Incretin synthesis, secretion, and inactivation 66
Show member pathways
 10.77 TCF7L2 LEP GIP GCG DPP4
10
Overview of nanoparticle effects 1
10.76 IL6 CRP
11
Transcription factor regulation in adipogenesis 1
10.6 PPARG LEP IL6 ADIPOQ
Sources

GO Terms for Prediabetes Syndrome

About this section

Cellular components related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 LEP INS IL6 GIP GCG CRP
2 secretory granule lumen GO:0034774 9.43 INS GIP GCG
3 endoplasmic reticulum lumen GO:0005788 9.35 INS IL6 GIP GCG ALB
4 extracellular region GO:0005576 9.32 LEP INS IL6 GIP GCG FNDC5

Biological processes related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 LEP INS IL6 DPP4 CNBP
2 response to drug GO:0042493 9.87 PPARG GIP GAD1 ADIPOQ
3 positive regulation of MAPK cascade GO:0043410 9.79 LEP INS IL6
4 response to nutrient GO:0007584 9.7 PPARG LEP ADIPOQ
5 response to glucose GO:0009749 9.63 TCF7L2 GIP ADIPOQ
6 regulation of fat cell differentiation GO:0045598 9.61 PPARG LEP
7 positive regulation of insulin receptor signaling pathway GO:0046628 9.6 LEP INS
8 positive regulation of cellular protein metabolic process GO:0032270 9.59 INS ADIPOQ
9 negative regulation of collagen biosynthetic process GO:0032966 9.58 PPARG IL6
10 fatty acid oxidation GO:0019395 9.58 PPARG ADIPOQ
11 glucose metabolic process GO:0006006 9.58 LEP INS ADIPOQ
12 negative regulation of gluconeogenesis GO:0045721 9.56 INS ADIPOQ
13 regulation of insulin secretion GO:0050796 9.56 LEP GIP GCG DPP4
14 locomotory exploration behavior GO:0035641 9.55 GAD1 DPP4
15 response to nutrient levels GO:0031667 9.54 LEP GIP ADIPOQ
16 regulation of fatty acid biosynthetic process GO:0042304 9.51 GIP ADIPOQ
17 acute-phase response GO:0006953 9.5 INS IL6 CRP
18 positive regulation of brown fat cell differentiation GO:0090336 9.49 INS FNDC5
19 negative regulation of blood vessel diameter GO:0097756 9.48 INS CRP
20 negative regulation of acute inflammatory response GO:0002674 9.43 PPARG INS
21 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.33 PPARG CRP ADIPOQ
22 negative regulation of lipid storage GO:0010888 9.13 LEP IL6 CRP
23 glucose homeostasis GO:0042593 9.02 TCF7L2 PPARG LEP INS ADIPOQ

Molecular functions related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 PPARG INS GCG DPP4 CRP ALB
2 hormone activity GO:0005179 9.1 LEP INS GIP GCG FNDC5 ADIPOQ
Sources

Sources for Prediabetes Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....